A Study to Compare the Effect of Two Blinded Doses of Casodex (ICI 176,334 100 mg and 150 mg daily) and Castration in the Treatment of Advanced Carcinoma of the Prostate
Not Applicable
Completed
- Conditions
- ProstateCancer
- Registration Number
- ISRCTN44967321
- Lead Sponsor
- AstraZeneca Clinical Research Group (UK)
- Brief Summary
1998 results in https://www.ncbi.nlm.nih.gov/pubmed/9510340 (added 21/01/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 0
Inclusion Criteria
1. Locally advanced stage T3 or T4 carcinoma of the prostate with prostate-specific antigen times five the upper limit of normal or metastatic disease
2. Gleason grade 2-10
3. Evaluable disease
4. Fit to receive treatment
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration